Report from the SWOG Radiation Oncology Committee: Research Objectives Workshop 2017

Publication Date:
2018-08-02
Publisher:
The American Association for Cancer Research (AACR)
Print ISSN:
1078-0432
Electronic ISSN:
1557-3265
Topics:
Medicine
Published by:
http://www.aacr.org/
_version_ 1836399019589369856
autor Okunieff, P., Casey-Sawicki, K., Lockney, N. A., Hoppe, B. S., Enderling, H., Pinnix, C., Welsh, J., Krishnan, S., Yothers, G., Brown, M., Knox, S., Bristow, R., Spellman, P., Mitin, T., Nabavizadeh, N., Jaboin, J., Manning, H. C., Feng, F., Galbraith, S., Solanki, A. A., Harkenrider, M. M., Tuli, R., Decker, R. H., Finkelstein, S. E., Hsu, C. C., Ha, C. S., Jagsi, R., Shumway, D., Daly, M., Wang, T. J. C., Fitzgerald, T. J., Laurie, F., Marshall, D. T., Raben, D., Constine, L., Thomas, C. R., Kachnic, L. A.
beschreibung The Radiation Therapy Committee of SWOG periodically evaluates its strategic plan in an effort to maintain a current and relevant scientific focus, and to provide a standard platform for future development of protocol concepts. Participants in the 2017 Strategic Planning Workshop included leaders in cancer basic sciences, molecular theragnostics, pharmaceutical and technology industries, clinical trial design, oncology practice, and statistical analysis. The committee discussed high-priority research areas, such as optimization of combined modality therapy, radiation oncology–specific drug design, identification of molecular profiles predictive of radiation-induced local or distant tumor responses, and methods for normal tissue-specific mitigation of radiation toxicity. The following concepts emerged as dominant questions ready for national testing: ( i ) what is the role of radiotherapy in the treatment of oligometastatic, oligorecurrent, and oligoprogressive disease? ( ii ) How can combined modality therapy be used to enhance systemic and local response? ( iii ) Can we validate and optimize liquid biopsy and other biomarkers (such as novel imaging) to supplement current response criteria to guide therapy and clinical trial design endpoints? ( iv ) How can we overcome deficiencies of randomized survival endpoint trials in an era of increasing molecular stratification factors? And ( v ) how can we mitigate treatment-related side effects and maximize quality of life in cancer survivors? The committee concluded that many aspects of these questions are ready for clinical evaluation and example protocol concepts are provided that could improve rates of cancer cure and quality of survival. Clin Cancer Res; 24(15); 3500–9. ©2018 AACR .
citation_standardnr 6312892
datenlieferant ipn_articles
feed_id 9363
feed_publisher The American Association for Cancer Research (AACR)
feed_publisher_url http://www.aacr.org/
insertion_date 2018-08-02
journaleissn 1557-3265
journalissn 1078-0432
publikationsjahr_anzeige 2018
publikationsjahr_facette 2018
publikationsjahr_intervall 7984:2015-2019
publikationsjahr_sort 2018
publisher The American Association for Cancer Research (AACR)
quelle Clinical Cancer Research
relation http://clincancerres.aacrjournals.org/cgi/content/short/24/15/3500?rss=1
search_space articles
shingle_author_1 Okunieff, P., Casey-Sawicki, K., Lockney, N. A., Hoppe, B. S., Enderling, H., Pinnix, C., Welsh, J., Krishnan, S., Yothers, G., Brown, M., Knox, S., Bristow, R., Spellman, P., Mitin, T., Nabavizadeh, N., Jaboin, J., Manning, H. C., Feng, F., Galbraith, S., Solanki, A. A., Harkenrider, M. M., Tuli, R., Decker, R. H., Finkelstein, S. E., Hsu, C. C., Ha, C. S., Jagsi, R., Shumway, D., Daly, M., Wang, T. J. C., Fitzgerald, T. J., Laurie, F., Marshall, D. T., Raben, D., Constine, L., Thomas, C. R., Kachnic, L. A.
shingle_author_2 Okunieff, P., Casey-Sawicki, K., Lockney, N. A., Hoppe, B. S., Enderling, H., Pinnix, C., Welsh, J., Krishnan, S., Yothers, G., Brown, M., Knox, S., Bristow, R., Spellman, P., Mitin, T., Nabavizadeh, N., Jaboin, J., Manning, H. C., Feng, F., Galbraith, S., Solanki, A. A., Harkenrider, M. M., Tuli, R., Decker, R. H., Finkelstein, S. E., Hsu, C. C., Ha, C. S., Jagsi, R., Shumway, D., Daly, M., Wang, T. J. C., Fitzgerald, T. J., Laurie, F., Marshall, D. T., Raben, D., Constine, L., Thomas, C. R., Kachnic, L. A.
shingle_author_3 Okunieff, P., Casey-Sawicki, K., Lockney, N. A., Hoppe, B. S., Enderling, H., Pinnix, C., Welsh, J., Krishnan, S., Yothers, G., Brown, M., Knox, S., Bristow, R., Spellman, P., Mitin, T., Nabavizadeh, N., Jaboin, J., Manning, H. C., Feng, F., Galbraith, S., Solanki, A. A., Harkenrider, M. M., Tuli, R., Decker, R. H., Finkelstein, S. E., Hsu, C. C., Ha, C. S., Jagsi, R., Shumway, D., Daly, M., Wang, T. J. C., Fitzgerald, T. J., Laurie, F., Marshall, D. T., Raben, D., Constine, L., Thomas, C. R., Kachnic, L. A.
shingle_author_4 Okunieff, P., Casey-Sawicki, K., Lockney, N. A., Hoppe, B. S., Enderling, H., Pinnix, C., Welsh, J., Krishnan, S., Yothers, G., Brown, M., Knox, S., Bristow, R., Spellman, P., Mitin, T., Nabavizadeh, N., Jaboin, J., Manning, H. C., Feng, F., Galbraith, S., Solanki, A. A., Harkenrider, M. M., Tuli, R., Decker, R. H., Finkelstein, S. E., Hsu, C. C., Ha, C. S., Jagsi, R., Shumway, D., Daly, M., Wang, T. J. C., Fitzgerald, T. J., Laurie, F., Marshall, D. T., Raben, D., Constine, L., Thomas, C. R., Kachnic, L. A.
shingle_catch_all_1 Report from the SWOG Radiation Oncology Committee: Research Objectives Workshop 2017
The Radiation Therapy Committee of SWOG periodically evaluates its strategic plan in an effort to maintain a current and relevant scientific focus, and to provide a standard platform for future development of protocol concepts. Participants in the 2017 Strategic Planning Workshop included leaders in cancer basic sciences, molecular theragnostics, pharmaceutical and technology industries, clinical trial design, oncology practice, and statistical analysis. The committee discussed high-priority research areas, such as optimization of combined modality therapy, radiation oncology–specific drug design, identification of molecular profiles predictive of radiation-induced local or distant tumor responses, and methods for normal tissue-specific mitigation of radiation toxicity. The following concepts emerged as dominant questions ready for national testing: ( i ) what is the role of radiotherapy in the treatment of oligometastatic, oligorecurrent, and oligoprogressive disease? ( ii ) How can combined modality therapy be used to enhance systemic and local response? ( iii ) Can we validate and optimize liquid biopsy and other biomarkers (such as novel imaging) to supplement current response criteria to guide therapy and clinical trial design endpoints? ( iv ) How can we overcome deficiencies of randomized survival endpoint trials in an era of increasing molecular stratification factors? And ( v ) how can we mitigate treatment-related side effects and maximize quality of life in cancer survivors? The committee concluded that many aspects of these questions are ready for clinical evaluation and example protocol concepts are provided that could improve rates of cancer cure and quality of survival. Clin Cancer Res; 24(15); 3500–9. ©2018 AACR .
Okunieff, P., Casey-Sawicki, K., Lockney, N. A., Hoppe, B. S., Enderling, H., Pinnix, C., Welsh, J., Krishnan, S., Yothers, G., Brown, M., Knox, S., Bristow, R., Spellman, P., Mitin, T., Nabavizadeh, N., Jaboin, J., Manning, H. C., Feng, F., Galbraith, S., Solanki, A. A., Harkenrider, M. M., Tuli, R., Decker, R. H., Finkelstein, S. E., Hsu, C. C., Ha, C. S., Jagsi, R., Shumway, D., Daly, M., Wang, T. J. C., Fitzgerald, T. J., Laurie, F., Marshall, D. T., Raben, D., Constine, L., Thomas, C. R., Kachnic, L. A.
The American Association for Cancer Research (AACR)
1078-0432
10780432
1557-3265
15573265
shingle_catch_all_2 Report from the SWOG Radiation Oncology Committee: Research Objectives Workshop 2017
The Radiation Therapy Committee of SWOG periodically evaluates its strategic plan in an effort to maintain a current and relevant scientific focus, and to provide a standard platform for future development of protocol concepts. Participants in the 2017 Strategic Planning Workshop included leaders in cancer basic sciences, molecular theragnostics, pharmaceutical and technology industries, clinical trial design, oncology practice, and statistical analysis. The committee discussed high-priority research areas, such as optimization of combined modality therapy, radiation oncology–specific drug design, identification of molecular profiles predictive of radiation-induced local or distant tumor responses, and methods for normal tissue-specific mitigation of radiation toxicity. The following concepts emerged as dominant questions ready for national testing: ( i ) what is the role of radiotherapy in the treatment of oligometastatic, oligorecurrent, and oligoprogressive disease? ( ii ) How can combined modality therapy be used to enhance systemic and local response? ( iii ) Can we validate and optimize liquid biopsy and other biomarkers (such as novel imaging) to supplement current response criteria to guide therapy and clinical trial design endpoints? ( iv ) How can we overcome deficiencies of randomized survival endpoint trials in an era of increasing molecular stratification factors? And ( v ) how can we mitigate treatment-related side effects and maximize quality of life in cancer survivors? The committee concluded that many aspects of these questions are ready for clinical evaluation and example protocol concepts are provided that could improve rates of cancer cure and quality of survival. Clin Cancer Res; 24(15); 3500–9. ©2018 AACR .
Okunieff, P., Casey-Sawicki, K., Lockney, N. A., Hoppe, B. S., Enderling, H., Pinnix, C., Welsh, J., Krishnan, S., Yothers, G., Brown, M., Knox, S., Bristow, R., Spellman, P., Mitin, T., Nabavizadeh, N., Jaboin, J., Manning, H. C., Feng, F., Galbraith, S., Solanki, A. A., Harkenrider, M. M., Tuli, R., Decker, R. H., Finkelstein, S. E., Hsu, C. C., Ha, C. S., Jagsi, R., Shumway, D., Daly, M., Wang, T. J. C., Fitzgerald, T. J., Laurie, F., Marshall, D. T., Raben, D., Constine, L., Thomas, C. R., Kachnic, L. A.
The American Association for Cancer Research (AACR)
1078-0432
10780432
1557-3265
15573265
shingle_catch_all_3 Report from the SWOG Radiation Oncology Committee: Research Objectives Workshop 2017
The Radiation Therapy Committee of SWOG periodically evaluates its strategic plan in an effort to maintain a current and relevant scientific focus, and to provide a standard platform for future development of protocol concepts. Participants in the 2017 Strategic Planning Workshop included leaders in cancer basic sciences, molecular theragnostics, pharmaceutical and technology industries, clinical trial design, oncology practice, and statistical analysis. The committee discussed high-priority research areas, such as optimization of combined modality therapy, radiation oncology–specific drug design, identification of molecular profiles predictive of radiation-induced local or distant tumor responses, and methods for normal tissue-specific mitigation of radiation toxicity. The following concepts emerged as dominant questions ready for national testing: ( i ) what is the role of radiotherapy in the treatment of oligometastatic, oligorecurrent, and oligoprogressive disease? ( ii ) How can combined modality therapy be used to enhance systemic and local response? ( iii ) Can we validate and optimize liquid biopsy and other biomarkers (such as novel imaging) to supplement current response criteria to guide therapy and clinical trial design endpoints? ( iv ) How can we overcome deficiencies of randomized survival endpoint trials in an era of increasing molecular stratification factors? And ( v ) how can we mitigate treatment-related side effects and maximize quality of life in cancer survivors? The committee concluded that many aspects of these questions are ready for clinical evaluation and example protocol concepts are provided that could improve rates of cancer cure and quality of survival. Clin Cancer Res; 24(15); 3500–9. ©2018 AACR .
Okunieff, P., Casey-Sawicki, K., Lockney, N. A., Hoppe, B. S., Enderling, H., Pinnix, C., Welsh, J., Krishnan, S., Yothers, G., Brown, M., Knox, S., Bristow, R., Spellman, P., Mitin, T., Nabavizadeh, N., Jaboin, J., Manning, H. C., Feng, F., Galbraith, S., Solanki, A. A., Harkenrider, M. M., Tuli, R., Decker, R. H., Finkelstein, S. E., Hsu, C. C., Ha, C. S., Jagsi, R., Shumway, D., Daly, M., Wang, T. J. C., Fitzgerald, T. J., Laurie, F., Marshall, D. T., Raben, D., Constine, L., Thomas, C. R., Kachnic, L. A.
The American Association for Cancer Research (AACR)
1078-0432
10780432
1557-3265
15573265
shingle_catch_all_4 Report from the SWOG Radiation Oncology Committee: Research Objectives Workshop 2017
The Radiation Therapy Committee of SWOG periodically evaluates its strategic plan in an effort to maintain a current and relevant scientific focus, and to provide a standard platform for future development of protocol concepts. Participants in the 2017 Strategic Planning Workshop included leaders in cancer basic sciences, molecular theragnostics, pharmaceutical and technology industries, clinical trial design, oncology practice, and statistical analysis. The committee discussed high-priority research areas, such as optimization of combined modality therapy, radiation oncology–specific drug design, identification of molecular profiles predictive of radiation-induced local or distant tumor responses, and methods for normal tissue-specific mitigation of radiation toxicity. The following concepts emerged as dominant questions ready for national testing: ( i ) what is the role of radiotherapy in the treatment of oligometastatic, oligorecurrent, and oligoprogressive disease? ( ii ) How can combined modality therapy be used to enhance systemic and local response? ( iii ) Can we validate and optimize liquid biopsy and other biomarkers (such as novel imaging) to supplement current response criteria to guide therapy and clinical trial design endpoints? ( iv ) How can we overcome deficiencies of randomized survival endpoint trials in an era of increasing molecular stratification factors? And ( v ) how can we mitigate treatment-related side effects and maximize quality of life in cancer survivors? The committee concluded that many aspects of these questions are ready for clinical evaluation and example protocol concepts are provided that could improve rates of cancer cure and quality of survival. Clin Cancer Res; 24(15); 3500–9. ©2018 AACR .
Okunieff, P., Casey-Sawicki, K., Lockney, N. A., Hoppe, B. S., Enderling, H., Pinnix, C., Welsh, J., Krishnan, S., Yothers, G., Brown, M., Knox, S., Bristow, R., Spellman, P., Mitin, T., Nabavizadeh, N., Jaboin, J., Manning, H. C., Feng, F., Galbraith, S., Solanki, A. A., Harkenrider, M. M., Tuli, R., Decker, R. H., Finkelstein, S. E., Hsu, C. C., Ha, C. S., Jagsi, R., Shumway, D., Daly, M., Wang, T. J. C., Fitzgerald, T. J., Laurie, F., Marshall, D. T., Raben, D., Constine, L., Thomas, C. R., Kachnic, L. A.
The American Association for Cancer Research (AACR)
1078-0432
10780432
1557-3265
15573265
shingle_title_1 Report from the SWOG Radiation Oncology Committee: Research Objectives Workshop 2017
shingle_title_2 Report from the SWOG Radiation Oncology Committee: Research Objectives Workshop 2017
shingle_title_3 Report from the SWOG Radiation Oncology Committee: Research Objectives Workshop 2017
shingle_title_4 Report from the SWOG Radiation Oncology Committee: Research Objectives Workshop 2017
timestamp 2025-06-30T23:36:19.259Z
titel Report from the SWOG Radiation Oncology Committee: Research Objectives Workshop 2017
titel_suche Report from the SWOG Radiation Oncology Committee: Research Objectives Workshop 2017
topic WW-YZ
uid ipn_articles_6312892